What's Hot

View all perspectives
      RT @synovialjoints: The overall risk of cancer and cardiovascular disease were decreased in RA treated with JAKi but the

      Dr. Antoni Chan synovialjoints

      1 year 5 months ago
      The overall risk of cancer and cardiovascular disease were decreased in RA treated with JAKi but there was no comparison with TNFi, Sung Soo Ahn, Abst#00132 #EULAR2023 @RheumNow https://t.co/9Bi6t6uuig
      RT @Yuz6Yusof: #EULAR2023 #OP0141 CAR T cell therapy to treat refractory #lupus took centre stage in 2022. Up to 2yrs da

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 5 months ago
      #EULAR2023 #OP0141 CAR T cell therapy to treat refractory #lupus took centre stage in 2022. Up to 2yrs data on 7 patients showed continued drug-free remission despite repopulation of naive B cells. No safety concerns. Intriguing to learn even longer-term follow-up @RheumNow https://t.co/lINDT32VBj
      RT @Yuz6Yusof: #EULAR2023 #OP0139 Should we aim for dual blockade in #lupus? A Phase 2 RCT showed more patients on ABBV-

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 5 months ago
      #EULAR2023 #OP0139 Should we aim for dual blockade in #lupus? A Phase 2 RCT showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + Upadacitinib (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs Placebo at 48Wks. No major malignancy or VTE concerns @RheumNow https://t.co/HEUbkzZwyl
      RT @synovialjoints: Biologic dose reduction based on disease activity resulted in 40% reduction in TNFi and did not seem

      Dr. Antoni Chan synovialjoints

      1 year 5 months ago
      Biologic dose reduction based on disease activity resulted in 40% reduction in TNFi and did not seem to cause disease deterioration from the 10 year DRESS Study by N van Herwaarden, Abst#OP00131 #EULAR2023 @RheumNow https://t.co/ncGPF9ODcF
      RT @Janetbirdope: JAKi are NOT associated w worse safety vs bDMARDs when adjusting for confounding. Did regulators get i

      Janet Pope Janetbirdope

      1 year 5 months ago
      JAKi are NOT associated w worse safety vs bDMARDs when adjusting for confounding. Did regulators get it wrong? #EULAR2023 @RheumNow #OP0116 https://t.co/ZNk0NI7Ky5
      RT @Yuz6Yusof: #EULAR2023 #OP0137 Most impressive Delta difference vs Control in #lupus! In Phase 3 RCT in China, more p

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 5 months ago
      #EULAR2023 #OP0137 Most impressive Delta difference vs Control in #lupus! In Phase 3 RCT in China, more patients in Telitacicept, BAFF/APRIL-i met SRI-4 (delta 44% if data imputed; 34% without) vs placebo. No major safety. Global Phase 3 RCT is in progress @RheumNow https://t.co/DUFRQ7pNUA
      RT @synovialjoints: Abatacept use in individuals at risk of RA reduced the rate of progression to RA during the treatmen

      Dr. Antoni Chan synovialjoints

      1 year 5 months ago
      Abatacept use in individuals at risk of RA reduced the rate of progression to RA during the treatment phase and împrovement in clinical symptoms over 2 years in the APIPPRA trial by Cope A, Abstr#OP0130 https://t.co/k0SFDHBRE9
      RT @Janetbirdope: #JAKi May decrease #cancers - age, male, #diabetes had more #cancer but NOT associated w drug prescrib

      Janet Pope Janetbirdope

      1 year 5 months ago
      #JAKi May decrease #cancers - age, male, #diabetes had more #cancer but NOT associated w drug prescribed AND LESS #malignancy & LESS #CVE in JAKi vs csDMARDs in huge admin database. Diff from other results OP0140 @RheumNow #EULAR2023 EFFECTIVE Rx of RA LOWERS CVE & cancer w JAKi! https://t.co/oQ3QeUZz3E
      RT @synovialjoints: In insufficient responders, additional Etanercept for 24 weeks (bio-induction) did not show a higher

      Dr. Antoni Chan synovialjoints

      1 year 5 months ago
      In insufficient responders, additional Etanercept for 24 weeks (bio-induction) did not show a higher response of DAS28-CRP compared to the standard COBRA-SLIM regime from the CARERA2020 study by Delphine Bertrand, Abstr#00129 #EULAR2023 @RheumNow https://t.co/BR1GusPGRP
      RT @Yuz6Yusof: #EULAR2023 #OP0136 New Biomarkers in #lupus nephritis? Indoxyl sulfate and cytosine metabolite serum leve

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 5 months ago
      #EULAR2023 #OP0136 New Biomarkers in #lupus nephritis? Indoxyl sulfate and cytosine metabolite serum levels were associated with kidney damage but not SLEDAI and reduced following therapy with anifrolumab in Phase 2 RCT @RheumNow https://t.co/URiKx9rmmU
      RT @Yuz6Yusof: #EULAR2023 #POS0627 Researchers in Manchester identified several proteins associated with subclinical car

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 5 months ago
      #EULAR2023 #POS0627 Researchers in Manchester identified several proteins associated with subclinical cardiovascular abnormalities on Cardiac MRI in Scleroderma using proteomics. Need validation. Could be useful for stratification and identify therapeutic targets @RheumNow https://t.co/55eNGhMu5f
      RT @Janetbirdope: Get Un ‘DRESSED’? Use of #etanercept or #adalimumab for #rheumatoidarthritis. #RCT of dose optimiz

      Janet Pope Janetbirdope

      1 year 5 months ago
      Get Un ‘DRESSED’? Use of #etanercept or #adalimumab for #rheumatoidarthritis. #RCT of dose optimization-observational f/u over 10 yrs with attempts to lower and even d/c Rx in #RA You CAN lower dose in many Pts & even d/c Rx and recapture. X-rays OK @RheumNow #EULAR2023 #OP0131 https://t.co/PGK5SQJ1WU
      RT @drdavidliew: As Jack himself pointed out - we’re looking at patients without loads of inflammation. For me, to get

      David Liew drdavidliew

      1 year 5 months ago
      As Jack himself pointed out - we’re looking at patients without loads of inflammation. For me, to get anything out of this population is very interesting. Adding this to ARIAA, it does make us think about which pre-RA might benefit from abatacept, and how. #EULAR2023 @RheumNow https://t.co/UKHfc1X8QM
      RT @drdavidliew: @RheumNow Safety is pretty good too - this is abatacept we are talking about here. Cost is a different

      David Liew drdavidliew

      1 year 5 months ago
      @RheumNow Safety is pretty good too - this is abatacept we are talking about here. Cost is a different question, as is the pharmacoeconomics, but at least it’s safe. One other thing about the study ⬇️ #EULAR2023 @RheumNow https://t.co/H3AdBsK8t9
      RT @drdavidliew: What’s more - if you have arthralgias and more autoantibodies than just ACPA IgG, then maybe abatacep

      David Liew drdavidliew

      1 year 5 months ago
      What’s more - if you have arthralgias and more autoantibodies than just ACPA IgG, then maybe abatacept might actually make a substantial difference. There is prob a population in whom abatacept substantially prevents RA developing. Is it safe? ⬇️ APIPPRA #EULAR2023 @RheumNow https://t.co/94Y7HrBuEp

      Podcasts

      • ACR24 - RHEUMATOID ARTHRITIS
      • ACR24 - IL - 17
      • ACR24 - JAK TYK2

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.